Diabetic Foot Ulcers - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2017, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 12, 6, 22, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents
 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Foot Ulcers - Overview 8
Diabetic Foot Ulcers - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Diabetic Foot Ulcers - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 27
ANP Technologies Inc 27
Anterogen Co Ltd 27
Boston Therapeutics Inc 28
CardioVascular BioTherapeutics Inc 28
Celgene Corp 29
Chrysalis BioTherapeutics Inc 29
CytoTools AG 30
EyeGene Inc 30
FirstString Research Inc 31
Genentech Inc 31
GlaxoSmithKline Plc 32
Human Stem Cells Institute 32
Izun Pharmaceuticals Corp 33
Lakewood-Amedex Inc 33
MediWound Ltd 34
NovaLead Pharma Pvt Ltd 34
Oneness Biotech Co Ltd 35
Osiris Therapeutics Inc 35
Pherecydes Pharma SA 36
RMB-Research GmbH 36
Serodus ASA 37
Stempeutics Research Pvt Ltd 37
Stratatech Corp 38
TechnoPhage SA 38
Theravasc Inc 39
Topadur Pharma AG 39
USV Pvt Ltd 40
viDA Therapeutics Inc 40
ViroMed Co Ltd 41
Diabetic Foot Ulcers - Drug Profiles 42
3K3A-APC - Drug Profile 42
ALLO-ASC - Drug Profile 44
ANP-017 - Drug Profile 46
AP-185 - Drug Profile 47
APO-2 - Drug Profile 48
AUP-16 - Drug Profile 49
becaplermin biosimilar - Drug Profile 50
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 51
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 53
CODA-001 - Drug Profile 54
CVBT-141B - Drug Profile 56
Cyndacel-M - Drug Profile 58
daprodustat - Drug Profile 60
diperoxochloric acid - Drug Profile 63
EG-Decorin - Drug Profile 67
epidermal growth factor biosimilar - Drug Profile 68
EscharEx - Drug Profile 69
esmolol hydrochloride - Drug Profile 72
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 73
Granexin - Drug Profile 74
Heberprot-P - Drug Profile 76
IMSP-001 - Drug Profile 77
Ipoxyn - Drug Profile 78
IZN-6D4 - Drug Profile 79
MT-003 - Drug Profile 80
NAS-911 - Drug Profile 81
Neovasculgen - Drug Profile 83
Nu-2 - Drug Profile 84
Nu-3 - Drug Profile 85
ON-101 - Drug Profile 87
OTI-1501 - Drug Profile 89
PDA-002 - Drug Profile 90
PP-2351 - Drug Profile 91
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 92
RG-7880 - Drug Profile 93
rusalatide acetate - Drug Profile 94
SER-190 - Drug Profile 98
sodium nitrite SR - Drug Profile 99
Statmicoll - Drug Profile 101
Stempeucel - Drug Profile 102
TOPN-53 - Drug Profile 105
TP-102 - Drug Profile 106
V-10 - Drug Profile 107
V-2248 - Drug Profile 108
VM-202 - Drug Profile 109
VTI-1000 Series - Drug Profile 113
VTI-3000 Series - Drug Profile 114
Diabetic Foot Ulcers - Dormant Projects 115
Diabetic Foot Ulcers - Discontinued Products 118
Diabetic Foot Ulcers - Product Development Milestones 119
Featured News & Press Releases 119
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 128
Disclaimer 129

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, H1 2017
Diabetic Foot Ulcers - Pipeline by Boston Therapeutics Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by Celgene Corp, H1 2017
Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1 2017
Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by Genentech Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1 2017
Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1 2017
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1 2017
Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H1 2017
Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H1 2017
Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1 2017
Diabetic Foot Ulcers - Pipeline by RMB-Research GmbH, H1 2017
Diabetic Foot Ulcers - Pipeline by Serodus ASA, H1 2017
Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H1 2017
Diabetic Foot Ulcers - Pipeline by Stratatech Corp, H1 2017
Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1 2017
Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H1 2017
Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H1 2017
Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H1 2017
Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H1 2017
Diabetic Foot Ulcers - Dormant Projects, H1 2017
Diabetic Foot Ulcers - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diabetic Foot Ulcers - Dormant Projects, H1 2017 (Contd..2), H1 2017
Diabetic Foot Ulcers - Discontinued Products, H1 2017